Nasdaq Marketscompaniesinvestment opinion
Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock? (opens at Nasdaq Markets in a new tab)
Eli Lilly has been active in acquisitions while its key drugs include Mounjaro, Zepbound, and Foundayo. The article assesses how recent deals may affect the stock.
